Evaluation of the safety and neuroprotective properties of the VCP inhibitor ML240 in large-animal and human retinal explants: a preclinical ex vivo investigation - Top-Institutions - MDSpire

Evaluation of the safety and neuroprotective properties of the VCP inhibitor ML240 in large-animal and human retinal explants: a preclinical ex vivo investigation

  • By

  • Ana-Cristina Almansa-García

  • Angela Armento

  • Bowen Cao

  • Anne-Sophie Petremann-Dumé

  • Stefano Salmaso

  • Paolo Caliceti

  • Cristine Henes

  • Sylvie Bolz

  • Ellen Kilger

  • Daniela Süsskind

  • Marius Ueffing

  • Blanca Arango-Gonzalez

  • January 10, 2026

  • 0 min

Share

Top Institutions in Ophthalmology

Brief introduction explaining scope and methodology.

  • #1

    Massachusetts Eye and Ear Infirmary, Harvard Medical School
    Massachusetts Eye and Ear Infirmary, Harvard Medical School

    Boston, MA

    Key Differentiators

    • Ophthalmology
    • Retinal Disease
    • Neuroprotection

  • #2

    Bascom Palmer Eye Institute, University of Miami
    Bascom Palmer Eye Institute, University of Miami

    Miami, FL

    Key Differentiators

    • Ophthalmology
    • Retinal Degeneration
    • Translational Research

  • #3

    Johns Hopkins Wilmer Eye Institute
    Johns Hopkins Wilmer Eye Institute

    Baltimore, MD

    Key Differentiators

    • Ophthalmology
    • Retinal Neuroscience
    • Neurodegeneration

  • #4

    University of California, San Francisco (UCSF) Department of Ophthalmology
    University of California, San Francisco (UCSF) Department of Ophthalmology

    San Francisco, CA

    Key Differentiators

    • Ophthalmology
    • Retinal Disease
    • Neuroprotection

  • #5

    National Eye Institute (NEI), National Institutes of Health
    National Eye Institute (NEI), National Institutes of Health

    Bethesda, MD

    Key Differentiators

    • Ophthalmology Research
    • Retinal Neuroprotection
    • Translational Science

Original Source(s)

Evaluation of the safety and neuroprotective properties of the VCP inhibitor ML240 in large-animal and human retinal explants: a preclinical ex vivo investigation

  • by Ana-Cristina Almansa-García, Angela Armento, Bowen Cao, Anne-Sophie Petremann-Dumé, Stefano Salmaso, Paolo Caliceti, Cristine Henes, Sylvie Bolz, Ellen Kilger, Daniela Süsskind, Marius Ueffing, Blanca Arango-Gonzalez

  • January 10, 2026

Related Content

Diabetic Retinal Disease Rates Narrow by Diabetes Type

US claims data showed rising prevalence of diabetic retinal disease in type 1 and type 2 diabetes, while incidence declined in type 1 diabetes and moved closer to type 2 rates by 2022.

Nonexudative Macular Neovascularization in Age-Related Macular Degeneration

Equal Pay in Ophthalmology? Not Yet

A decade of AAMC salary data reveals a persistent gender pay gap in academic ophthalmology—and projects it will never close at senior ranks